Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$994.0K+846.67%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Craig Wichner
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 118
- Beta
- 1.59
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.38
Financials
Revenue
$994.0K+846.7%Net Income
$-22.14MEBITDA
$-11.50MFree Cash Flow
$-9.37MEPS (diluted)
$-0.29Shares Outstanding (diluted)
76.76M+13779.9%Operating Expenses
$12.76MCash & Debt
$20.43MReturn of Capital
$0.00Revenue by Segment (annual)
$3.64MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.64M | $-127.08M | $-2.78 |
| 2024 | $4.26M | $-251.39M | $-10.83 |
| 2023 | $1.82M | $-267.63M | $-25.95 |
| 2022 | $157.0K | $-16.89M | $-18.36 |
| 2021 | $25.99M | $-29.20M | $-38.96 |
| 2020 | $23.85M | $-44.84M | $-66.16 |
| 2019 | $7.30M | $-39.61M | $-60.37 |
| 2018 | $236.0K | $-27.90M | $-45.46 |
| 2017 | $508.0K | $-25.98M | $-46.86 |
| 2016 | $399.0K | $-12.09M | $-21.86 |
| 2015 | $1.27M | $-5.89M | $-10.65 |
Valuation
CBUShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-65.32%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·7d ago·Neutral
Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop Collaboration pairs Cibus' platform for improving a plant's own genes with Crystal Crop's mustard varieties and its reach across India, with the goal of putting better-performing seed in growers' hands in a fraction of the time of conventional breeding Collaboration pairs Cibus' platform for improving a plant's own genes with Crystal Crop's mustard varieties and its reach across India, with the goal of putting better-perfo
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript Cibus, Inc. (CBUS) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·53d ago·Negative
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates Cibus (CBUS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.61 per share a year ago.
View source ↗ - Newsmarketbeat.com·53d ago·Negative
Cibus Q2 Earnings Call Highlights Cibus NASDAQ: CBUS reported second-quarter 2026 revenue of $1.0 million, compared with $0.9 million a year earlier, as the agricultural biotechnology company advanced its Sustainable Ingredients program and updated the expected timing of its initial rice launch in Latin America.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
…NA as conventionally bred Quarterly net cash usage declined 19% sequentially and 31% year over year SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a technology company that uses biology to produce sustainable ingredients and helps farmers grow more food with fewer inputs, today announced its financial results for the quarter ended June 30, 2026, and provided a business update. Management will host a conference call and webcast today at 4:30 p.m.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.20 per share
Typical surprise -7.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.29 vs $-0.19miss
- Thu, May 14$-0.33 vs $-0.35beat
- Tue, Mar 17$-0.42 vs $-0.43beat
- Thu, Nov 13$-0.44 vs $-0.41miss
- Thu, Aug 14$-0.61 vs $-0.69beat
- Thu, May 8$-1.34 vs $-0.70miss
Estimates and results for CBUS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CBUS officers and directors.
- Bought
- —
- Sold
- $96k
0 trades
35 trades
- Sauer Noelsold
- Prante Gerhardsold
- Prante Gerhardsold
- Prante Gerhardsold
- Prante Gerhardsold
- Prante Gerhardsold
- Prante Gerhardsold
- Prante Gerhardsold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CBUS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.